RT Journal Article
SR Electronic
T1 EORTC QLQ-BM22 Quality of Life Evaluation and Pain Outcome in Patients with Bone Metastases from Breast Cancer Treated with Zoledronic Acid
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1001
OP 1004
VO 28
IS 5
A1 YEH, DAH-CHERNG
A1 CHEN, DAR-REN
A1 CHAO, TSU-YI
A1 CHEN, SHIN-CHEH
A1 WANG, HWEI-CHUNG
A1 RAU, KUN-MING
A1 FENG, YIN-HSUN
A1 CHANG, YUAN-CHING
A1 LEE, KUAN-DER
A1 OU-YANG, FU
A1 KUO, WEN-HUNG
A1 CHANG, KING-JEN
A1 LIN, YUNG-CHANG
A1 TSENG, LING-MING
A1 HOU, MING-FENG
YR 2014
UL http://iv.iiarjournals.org/content/28/5/1001.abstract
AB Background: We assessed the effect of zoledronic acid on quality of life (QOL) and pain outcome in breast cancer patients with bone metastases using the European Organization for Research and Treatment of Cancer bone metastases module (EORTC QLQ-BM22). Patients and Methods: Three hundred sixty-six breast cancer patients receiving zoledronic acid for bone metastases from 13 Centers were prospectively enrolled. QOL was evaluated using the EORTC QLQ-BM22 and pain outcome were measured monthly with a Visual Analog Scale (VAS) score for 24 months. Results: No significant change of functional scale (functional interference and psychosocial aspects) of the EORTC QLQ-BM22 was reported. Significant reduction of the symptom scale was noted after treatment compared with the baseline. The painful site subscale was significantly reduced during the first 12 months, with the exception the 6-month follow-up of point. Pain characteristics subscale was also significantly lower from the 2-month time point onwards. VAS scores indicated a significant reduction in pain over the course of the study to the 22-month time point follow-up compared to the baseline. Conclusion: Zoledronic acid treatment improved QOL of breast cancer patients with bone metastases by relieving bone pain.